Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Ann

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Bioorganic & Medicinal Chemistry Letters|March 20, 2003
The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2Josie A Blackie, Jackie C Bloomer, Murray J B Brown, et al.
Bioorganic & Medicinal Chemistry Letters|August 17, 2002
The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in manJosie A Blackie, Jackie C Bloomer, Murray J B Brown, et al.
Plos Clinical Trials|November 25, 2006
Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan childrenMark R Withers, Denise McKinney, Bernhards R Ogutu, et al.
Vaccine|April 20, 2007
Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of ResearchMark E Polhemus, Alan J Magill, James F Cummings, et al.
Plos One|March 6, 2009
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western KenyaBernhards R Ogutu, Odika J Apollo, Denise McKinney, et al.
Vaccine|September 10, 2009
Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infectionJames F Cummings, Michele D Spring, Robert J Schwenk, et al.
Plos One|April 25, 2009
Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02AMichele D Spring, James F Cummings, Christian F Ockenhouse, et al.
Plos One|January 24, 2008
Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trialMahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, et al.
Vaccine|March 10, 2005
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of ResearchD Gray Heppner, Kent E Kester, Christian F Ockenhouse, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Bioorganic & Medicinal Chemistry Letters|March 20, 2003
The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2Josie A Blackie, Jackie C Bloomer, Murray J B Brown, et al.
Bioorganic & Medicinal Chemistry Letters|August 17, 2002
The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in manJosie A Blackie, Jackie C Bloomer, Murray J B Brown, et al.
Plos Clinical Trials|November 25, 2006
Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan childrenMark R Withers, Denise McKinney, Bernhards R Ogutu, et al.
Vaccine|April 20, 2007
Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of ResearchMark E Polhemus, Alan J Magill, James F Cummings, et al.
Plos One|March 6, 2009
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western KenyaBernhards R Ogutu, Odika J Apollo, Denise McKinney, et al.
Vaccine|September 10, 2009
Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infectionJames F Cummings, Michele D Spring, Robert J Schwenk, et al.
Plos One|April 25, 2009
Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02AMichele D Spring, James F Cummings, Christian F Ockenhouse, et al.
Plos One|January 24, 2008
Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trialMahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, et al.
Vaccine|March 10, 2005
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of ResearchD Gray Heppner, Kent E Kester, Christian F Ockenhouse, et al.
Pageof 6